IT202100020846A1 - NEW VETERINARY USE OF A VEGETABLE OIL - Google Patents
NEW VETERINARY USE OF A VEGETABLE OIL Download PDFInfo
- Publication number
- IT202100020846A1 IT202100020846A1 IT102021000020846A IT202100020846A IT202100020846A1 IT 202100020846 A1 IT202100020846 A1 IT 202100020846A1 IT 102021000020846 A IT102021000020846 A IT 102021000020846A IT 202100020846 A IT202100020846 A IT 202100020846A IT 202100020846 A1 IT202100020846 A1 IT 202100020846A1
- Authority
- IT
- Italy
- Prior art keywords
- milk
- vegetable oil
- oil
- mastitis
- cells
- Prior art date
Links
- 235000015112 vegetable and seed oil Nutrition 0.000 title claims description 49
- 239000008158 vegetable oil Substances 0.000 title claims description 49
- 235000013336 milk Nutrition 0.000 claims description 44
- 239000008267 milk Substances 0.000 claims description 44
- 210000004080 milk Anatomy 0.000 claims description 44
- 208000004396 mastitis Diseases 0.000 claims description 37
- 241001465754 Metazoa Species 0.000 claims description 21
- 210000001082 somatic cell Anatomy 0.000 claims description 21
- 239000003921 oil Substances 0.000 claims description 20
- 235000019198 oils Nutrition 0.000 claims description 20
- 235000013365 dairy product Nutrition 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 16
- 150000002978 peroxides Chemical class 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 244000052769 pathogen Species 0.000 claims description 6
- 241000194017 Streptococcus Species 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 206010037660 Pyrexia Diseases 0.000 claims description 3
- 241000191967 Staphylococcus aureus Species 0.000 claims description 3
- 241000193985 Streptococcus agalactiae Species 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 241000194054 Streptococcus uberis Species 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229940115922 streptococcus uberis Drugs 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 description 12
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 10
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 10
- 210000005075 mammary gland Anatomy 0.000 description 8
- 235000020778 linoleic acid Nutrition 0.000 description 6
- 235000021313 oleic acid Nutrition 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 5
- 239000005642 Oleic acid Substances 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 5
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000207836 Olea <angiosperm> Species 0.000 description 4
- 240000007817 Olea europaea Species 0.000 description 4
- 235000002725 Olea europaea Nutrition 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 235000019487 Hazelnut oil Nutrition 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 239000008169 grapeseed oil Substances 0.000 description 2
- 239000010468 hazelnut oil Substances 0.000 description 2
- 239000010460 hemp oil Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000944 linseed oil Substances 0.000 description 2
- 235000021388 linseed oil Nutrition 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002018 neem oil Substances 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000008171 pumpkin seed oil Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000010497 wheat germ oil Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000001720 action spectrum Methods 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002432 hydroperoxides Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pregnancy & Childbirth (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Lubricants (AREA)
Description
Sezione Classe Sottoclasse Gruppo Sottogruppo Section Class Subclass Group Subgroup
A 61 K 36 88 A 61 K 36 88
Sezione Classe Sottoclasse Gruppo Sottogruppo Section Class Subclass Group Subgroup
A 61 K 36 899 A 61K 36 899
Titolo Title
NUOVO USO VETERINARIO DI UN OLIO VEGETALE NEW VETERINARY USE OF A VEGETABLE OIL
DESCRIZIONE DESCRIPTION
Annessa a domanda di brevetto per INVENZIONE INDUSTRIALE avente per titolo Attached to a patent application for INDUSTRIAL INVENTION having the title
?NUOVO USO VETERINARIO DI UN OLIO VEGETALE? ?NEW VETERINARY USE OF A VEGETABLE OIL?
CAMPO DELL?INVENZIONE FIELD OF THE INVENTION
La presente invenzione ha per oggetto un olio vegetale ozonizzato per l?uso nel trattamento o nella prevenzione di una mastite in un animale da latte. The present invention relates to an ozonated vegetable oil for use in the treatment or prevention of mastitis in a dairy animal.
STATO DELL?ARTE STATE OF ART
La mastite ? un'infiammazione della ghiandola mammaria che provoca cambiamenti nella composizione biochimica del latte e nel tessuto della ghiandola. Mastitis? an inflammation of the mammary gland that causes changes in the biochemical composition of the milk and in the tissue of the gland.
? una delle malattie pi? comuni delle mucche o vacche da latte, in particolar modo nella razza Frisona, una delle pi? usate per produrre il latte. La mastite ha un impatto negativo nella qualit? e nella quantit? di latte prodotto, tanto da causare perdite per l?allevatore. Se la patologia non viene tratta in tempo, pu? diventare cronica, rendendo necessario il sacrificio dell?animale. ? one of the most common diseases common of cows or dairy cows, especially in the Friesian breed, one of the most? used to produce milk. Does mastitis have a negative impact on the quality? and in the quantity? of milk produced, so as to cause losses for the farmer. If the disease is not treated in time, it can become chronic, making it necessary to sacrifice the animal.
La mastite ? una malattia multifattoriale poich? l'infezione dipende dai germi, dalle condizioni ambientali e dalle caratteristiche della mucca. I microrganismi invadono il tessuto mammario provocando un'infiammazione della ghiandola. Mastitis? a multifactorial disease since? the infection depends on the germs, the environmental conditions and the characteristics of the cow. The microorganisms invade the breast tissue causing inflammation of the gland.
La malattia presenta due eziologie principali: la mastite contagiosa causata da microrganismi che vivono nella ghiandola mammaria (principalmente Streptococcus agalactiae e Staphylococcus aureus) e la mastite ambientale, causata da microrganismi (streptococchi ambientali e coliformi) che vivono nell'ambiente e che vengono trasmessi fra mungitura e il periodo secco durante il quale la ghiandola non produce latte. The disease has two main etiologies: contagious mastitis caused by microorganisms living in the mammary gland (mainly Streptococcus agalactiae and Staphylococcus aureus) and environmental mastitis, caused by microorganisms (environmental streptococci and coliforms) living in the environment and transmitted between milking and the dry period during which the gland does not produce milk.
A seconda della sintomatologia, la mastite viene classificata come: Depending on the symptoms, mastitis is classified as:
- mastite subclinica, dove non si osservano alterazioni nel latte e/o nelle mammelle, ma la quantit? di microrganismi e di cellule somatiche ? elevata; - subclinical mastitis, where no changes are observed in the milk and/or udders, but the quantity? of microorganisms and somatic cells ? high;
- mastite clinica, con infiammazione e dolore per l?animale, latte alterato che presenta desquamazioni, coaguli, siero scolorito e a volte sangue; e - clinical mastitis, with inflammation and pain for the animal, spoiled milk with scaling, clots, discolored serum and sometimes blood; And
- mastite acuta che mette a rischio la vita dell'animale, con febbre, perdita di appetito o minor produzione di latte. - acute mastitis which puts the animal's life at risk, with fever, loss of appetite or reduced milk production.
Uno dei parametri che viene maggiormente valutato, e che ? indice di un inizio della mastite, ? la conta delle cellule somatiche nel latte. Infatti, un aumento della conta delle cellule somatiche nel latte ? indice di un?infiammazione della ghiandola mammaria: pi? di 200.000 cellule/ml di latte sono indice di una mastite subclinica. One of the parameters that is most evaluated, and what? index of an onset of mastitis, ? somatic cell count in milk. In fact, an increase in somatic cell counts in milk ? index of an inflammation of the mammary gland: pi? of 200,000 cells/ml of milk are indicative of a subclinical mastitis.
L?attuale trattamento standard per la mastite prevede l?uso di antibiotici. Il latte deve quindi essere eliminato per 15 giorni e, oltre al rischio di contaminazione della filiera alimentare e il possibile sviluppo di resistenza agli antibiotici, c?? anche la sofferenza delle mucche infette. Pertanto, c?? la necessit? di avere un trattamento che consenta il ripristino della salute dell?animale evitando la predita produttiva per l?allevatore. The current standard treatment for mastitis involves the use of antibiotics. The milk must then be eliminated for 15 days and, in addition to the risk of contamination of the food chain and the possible development of resistance to antibiotics, c?? also the suffering of infected cows. Therefore, c?? the need? to have a treatment that allows the animal?s health to be restored while avoiding the production loss for the farmer.
SOMMARIO DELL?INVENZIONE SUMMARY OF THE INVENTION
Un primo aspetto della presente invenzione riguarda un olio vegetale ozonizzato o una composizione che lo comprende per l?uso nella prevenzione o nel trattamento di una mastite in un animale da latte. Preferibilmente, l?olio vegetale ozonizzato ? somministrato a livello mammario, preferibilmente per via endocanicolare, ovvero nel canalicolo mammario. Preferibilmente, l?olio vegetale ozonizzato ha un indice di perossido IP ? 2000 mEq O2/Kg, pi? preferibilmente compreso tra 350 ? 2000 mEq O2/Kg. A first aspect of the present invention relates to an ozonated vegetable oil or a composition comprising it for use in the prevention or treatment of mastitis in a dairy animal. Preferably, ozonated vegetable oil is administered at the mammary level, preferably by the endocanicular route, i.e. in the mammary canaliculus. Preferably, the ozonated vegetable oil has a peroxide index IP ? 2000 mEq O2/Kg, plus? preferably between 350 ? 2000 mEq O2/Kg.
Un secondo aspetto della presente invenzione riguarda un kit comprendente almeno un dispositivo per una somministrazione endocanicolare ed un olio vegetale ozonizzato. Preferibilmente, l?olio vegetale ozonizzato ? l?olio vegetale ozonizzato sopra descritto. A second aspect of the present invention relates to a kit comprising at least one device for intracanicular administration and an ozonated vegetable oil. Preferably, ozonated vegetable oil is the ozonated vegetable oil described above.
DEFINIZIONI DEFINITIONS
Nel contesto della presente invenzione, con il termine ?dispersione? ci si riferisce a un sistema eterogeneo costituito da una fase liquida prevalente (fase disperdente o fase continua) in cui ? dispersa una fase liquida immiscibile con la fase disperdente (fase dispersa). Le gocce che costituiscono la fase dispersa possono avere dimensioni maggiori o uguali a circa 10<-3 >?m. Nel contesto della presente invenzione, con il termine ?emulsione? ci si riferisce ad una dispersione in cui le gocce che costituiscono la fase dispersa hanno dimensioni circa 10<-3 >? 1 ?m. In the context of the present invention, with the term ?dispersion? we refer to a heterogeneous system consisting of a prevalent liquid phase (dispersing phase or continuous phase) in which ? dispersed a liquid phase immiscible with the dispersing phase (dispersed phase). The drops constituting the dispersed phase can have dimensions greater than or equal to about 10<-3 >?m. In the context of the present invention, with the term ?emulsion? are we referring to a dispersion in which the drops that make up the dispersed phase have dimensions of approximately 10<-3 >? 1 ?m.
Con il termine ?olio vegetale? ci si riferisce nella presente descrizione e nelle rivendicazioni allegate ad una miscela liquida a 25?C e 101,3 kPa costituita prevalentemente da lipidi esterificati, ricavata generalmente da frutti e/o semi di piante oleose. With the term ?vegetable oil? reference is made in the present description and in the attached claims to a liquid mixture at 25°C and 101.3 kPa mainly consisting of esterified lipids, generally obtained from fruits and/or seeds of oily plants.
Nel contesto della presente invenzione, i termini ?acido oleico?, ?acido linoleico? e, pi? in generale ?acido grasso?, si riferiscono agli acidi rispettivamente oleico, linoleico e grasso presenti in un olio vegetale in forma esterificata, preferibilmente sotto forma di trigliceridi. Il termine ?acido grasso libero? ? utilizzato nel contesto della presente invenzione ad indicare un acido grasso non esterificato. In the context of the present invention, the terms ?oleic acid?, ?linoleic acid? and, more in general ?fatty acid? refer to respectively oleic, linoleic and fatty acids present in a vegetable oil in esterified form, preferably in the form of triglycerides. The term ?free fatty acid? ? used in the context of the present invention to mean a non-esterified fatty acid.
Nel contesto della presente invenzione, con il termine ?indice di perossido (IP)? si intende la quantit? e la qualit? degli acidi grassi insaturi presenti, i quali danno luogo a diverse reazioni di perossidazione in presenza di ozono. I prodotti perossidati che si formano, ad esempio perossidi, idroperossidi e ozonidi, sono responsabili dell?elevato spettro di azione terapeutica degli oli ozonizzati. In the context of the present invention, with the term ?peroxide index (PI)? do you mean the quantity? and the quality? of the unsaturated fatty acids present, which give rise to various peroxidation reactions in the presence of ozone. The peroxidized products that are formed, for example peroxides, hydroperoxides and ozonides, are responsible for the high therapeutic action spectrum of ozonated oils.
Nel contesto della presente invenzione, con il termine ?mEq O2/Kg? si intende i milliequivalenti di ossigeno per chilo di olio. In the context of the present invention, with the term ?mEq O2/Kg? means the milliequivalents of oxygen per kilo of oil.
Nel contesto della presente invenzione, per ?conta delle cellule somatiche in condizioni normali non patologiche? si intende un conta delle cellule somatiche nel latte inferiore a 2*10<5 >cellule/ml di latte per una vacca pluripara ed inferiore a 1*10<5 >cellule/ml di latte per una vacca primipara. In the context of the present invention, for ?somatic cell count in normal nonpathological conditions? it means a count of somatic cells in milk lower than 2*10<5 >cells/ml of milk for a pluriparous cow and lower than 1*10<5 >cells/ml of milk for a primiparous cow.
DESCRIZIONE DETTAGLIATA DELL?INVENZIONE DETAILED DESCRIPTION OF THE INVENTION
Un primo aspetto della presente invenzione riguarda un olio vegetale ozonizzato o una composizione che lo comprende per l?uso nella prevenzione o nel trattamento di una mastite in un animale da latte. A first aspect of the present invention relates to an ozonated vegetable oil or a composition comprising it for use in the prevention or treatment of mastitis in a dairy animal.
In una forma di realizzazione, l?olio ozonizzato ? somministrato a livello mammario, preferibilmente per via endocanicolare, ovvero nel canalicolo mammario. In one embodiment, the ozonated oil is administered at the mammary level, preferably by the endocanicular route, i.e. in the mammary canaliculus.
In una forma di realizzazione, l?olio vegetale comprende acido oleico (C18:1) e acido linoleico (C18:2) in quantit? complessiva maggiore o uguale a 35% in peso. Preferibilmente, l?olio vegetale comprende complessivamente circa 35-85% in peso, preferibilmente circa 50-80% in peso, pi? preferibilmente circa 55?75% in peso, di acido oleico (C18:1) e acido linoleico (C18:2). In one embodiment, the vegetable oil comprises oleic acid (C18:1) and linoleic acid (C18:2) in amounts greater than or equal to 35% by weight. Preferably, the vegetable oil comprises overall about 35-85% by weight, preferably about 50-80% by weight, plus? preferably about 55-75% by weight, of oleic acid (C18:1) and linoleic acid (C18:2).
In una forma di attuazione dell?invenzione, l?olio vegetale ozonizzato ? scelto nel gruppo costituito da olio di arachidi, olio di mais, olio di girasole, olio di colza, olio di sesamo, olio di riso, olio di germe di grano, olio di semi di canapa, olio di soia, olio di lino, olio di mandorla, olio di neem, olio di nocciola, olio di vinaccioli, olio di semi di zucca e loro miscele. Preferibilmente, l?olio vegetale ozonizzato non ? olio di oliva, ovvero ? diverso da un olio derivante dalla spremitura dei frutti dell?ulivo e/o dalla sansa delle olive. In one embodiment of the invention, the ozonated vegetable oil is selected from the group consisting of peanut oil, corn oil, sunflower oil, rapeseed oil, sesame oil, rice oil, wheat germ oil, hemp seed oil, soybean oil, linseed oil, oil, neem oil, hazelnut oil, grapeseed oil, pumpkin seed oil, and blends thereof. Preferably, ozonated vegetable oil is not olive oil or ? different from an oil deriving from the pressing of the fruits of the olive tree and/or from the pomace of the olives.
In una forma di realizzazione alternativa dell?invenzione, l?olio vegetale ozonizzato ? olio di oliva, ovvero un olio derivante dalla spremitura dei frutti dell?ulivo e/o dalla sansa delle olive. In an alternative embodiment of the invention, the ozonated vegetable oil is olive oil, or an oil deriving from the pressing of the fruits of the olive tree and/or from the pomace of the olives.
In una forma di realizzazione, l?olio vegetale ozonizzato ha una viscosit? e indice di perossido controllati. In one embodiment, the ozonated vegetable oil has a viscosity of and peroxide index checked.
Preferibilmente, l?olio vegetale ozonizzato ha un indice di perossido IP ? 2000 mEq O2/Kg, pi? preferibilmente compreso tra 350 ? 2000 mEq O2/Kg. In una forma di attuazione preferita dell?invenzione, l?olio vegetale ozonizzato ha un indice di perossido compreso tra 350 ? 1000 mEq O2/Kg, preferibilmente tra 400 ? 800 mEq O2/Kg. Preferably, the ozonated vegetable oil has a peroxide index IP ? 2000 mEq O2/Kg, plus? preferably between 350 ? 2000 mEq O2/Kg. In a preferred embodiment of the invention, the ozonated vegetable oil has a peroxide index of between 350 ? 1000 mEq O2/Kg, preferably between 400 ? 800 mEq O2/Kg.
In una forma di attuazione, l?olio vegetale ozonizzato ? una dispersione acqua in olio oppure un?emulsione acqua in olio oppure ancora un gel, preferibilmente un gel stabile. In una forma di realizzazione preferita dell?invenzione, l?olio ozonizzato ? un gel stabile. In one embodiment, the ozonated vegetable oil is a water-in-oil dispersion or a water-in-oil emulsion or a gel, preferably a stable gel. In a preferred embodiment of the invention, the ozonated oil is a stable gel.
In una forma di attuazione, l?animale da latte ? un bovino, preferibilmente ? una vacca da latte, oppure ? un ovino, preferibilmente una pecora o una capra. In una forma di realizzazione preferita dell?invenzione, l?animale da latte ? una vacca. In one embodiment, the dairy animal is a bovine, preferably ? a dairy cow, or ? a sheep, preferably a sheep or a goat. In a preferred embodiment of the invention, the dairy animal is a cow.
In una forma di realizzazione, la mastite ? una mastite clinica, ovvero caratterizzata da modificazioni evidenti della ghiandola mammaria e del latte. La mastite clinica ? preferibilmente caratterizzata da un aumento della conta di cellule somatiche nel latte rispetto alla conta di cellule somatiche in condizioni normali, ovvero non patologiche. In one embodiment, mastitis ? a clinical mastitis, that is characterized by evident modifications of the mammary gland and of the milk. Clinical mastitis? preferably characterized by an increase in the somatic cell count in milk relative to the somatic cell count under normal, i.e., non-pathological conditions.
Preferibilmente, la conta di cellule somatiche nel latte ? superiore a 2,5*10<5 >cellule/ml di latte, preferibilmente superiore a 3*10<5 >cellule/ml di latte. Preferably, the somatic cell count in milk ? higher than 2.5*10<5 >cells/ml of milk, preferably higher than 3*10<5 >cells/ml of milk.
In una forma di attuazione, la mastite ? una mastite subclinica, ovvero non sono evidenti modificazioni a livello della ghiandola mammaria e del latte. La mastite subclinica ? preferibilmente caratterizzata da una riduzione della quantit? del latte prodotto e ad un aumento della conta di cellule somatiche nel latte rispetto alla conta di cellule somatiche in condizioni normali, ovvero non patologiche. Preferibilmente, la conta di cellule somatiche nel latte superiore a 1,5*10<5 >cellule/ml di latte, preferibilmente superiore a 2*10<5 >cellule/ml di latte. In one embodiment, mastitis ? a subclinical mastitis, ie there are no obvious changes in the mammary gland and milk. Subclinical mastitis? preferably characterized by a reduction in the quantity? of milk produced and an increase in somatic cell counts in milk relative to somatic cell counts under normal, i.e., non-pathological, conditions. Preferably, the somatic cell count in the milk greater than 1.5*10<5>cells/ml of milk, preferably greater than 2*10<5>cells/ml of milk.
In una ulteriore forma di realizzazione, la mastite ? una mastite acuta, ovvero caratterizzata da febbre, dolore, una diminuzione della produzione di latte e aumento delle cellule somatiche. In a further embodiment, mastitis is an acute mastitis, or characterized by fever, pain, a decrease in milk production and an increase in somatic cells.
In una ulteriore forma di attuazione, la mastite ? causata da almeno un agente patogeno, preferibilmente detto agente patogeno ? un virus o un batterio o un fungo. Preferibilmente, detto almeno un agente patogeno ? un batterio, pi? preferibilmente ? un batterio scelto tra: Streptococco mastidogeno, preferibilmente Streptococcus uberis, Streptococcus dygalactiae, Streptococcus agalactiae, Staphylococcus aureus ed Escherichia Coli. In a further embodiment, mastitis ? caused by at least one pathogen, preferably said pathogen ? a virus or a bacterium or a fungus. Preferably, said at least one pathogen ? a bacterium, more preferably ? a bacterium selected from: Mastidogenic Streptococcus, preferably Streptococcus uberis, Streptococcus dygalactiae, Streptococcus agalactiae, Staphylococcus aureus and Escherichia Coli.
L?olio vegetale ozonizzato viene somministrato almeno 2 volte ogni 24 ore preferibilmente durante la mungitura, pi? preferibilmente viene somministrato prima e/o dopo la mungitura dell?animale da latte. In una forma di attuazione preferita dell?invenzione, l?olio ozonizzato viene somministrato almeno 2 volte al giorno dopo la mungitura dell?animale da latte. Preferibilmente, l?olio vegetale ozonizzato viene somministrato prima e/o dopo la mungitura per almeno 2 mungiture consecutive, pi? preferibilmente per almeno 4 mungiture consecutive. The ozonated vegetable oil is administered at least 2 times every 24 hours, preferably during milking, plus? it is preferably administered before and/or after milking the dairy animal. In a preferred embodiment of the invention, the ozonated oil is administered at least twice a day after milking the dairy animal. Preferably, the ozonated vegetable oil is administered before and/or after milking for at least 2 consecutive milkings, plus? preferably for at least 4 consecutive milkings.
In una ulteriore forma di realizzazione, l?olio vegetale ozonizzato ? utilizzato per gli scopi sopra descritti in associazione o in combinazione con almeno un trattamento per la mastite in un animale da latte. Preferibilmente, detto almeno un trattamento ? scelto tra: almeno un antibiotico, almeno un antifungino, igiene delle mammelle e interruzione della mungitura. In a further embodiment, the ozonated vegetable oil is used for the purposes described above in association or in combination with at least one treatment for mastitis in a dairy animal. Preferably, said at least one treatment ? chosen from: at least one antibiotic, at least one antifungal, udder hygiene and milking interruption.
In una forma di realizzazione, l?olio vegetale ozonizzato ? ottenuto con un processo noto al tecnico del settore. In one embodiment, the ozonated vegetable oil is obtained with a process known to those skilled in the art.
La Richiedente ha sorprendentemente scoperto che la somministrazione di olio vegetale ozonizzato per via endocanicolare ? in grado di trattare o di prevenire una mastite in un animale da latte. Senza volersi legare ad alcuna teoria, la presenza di perossidi nell?olio ozonizzato ? in grado di prevenire o di trattare infezioni patogene distruggendo le cellule batteriche e/o fungine. Inoltre, l?olio vegetale ozonizzato ha un?azione cicatrizzante grazie alla capacit? di stimolare i fibroblasti ed indurre la neoangiogenesi. Infine, la somministrazione di olio ozonizzante per via endocanicolare ha un?azione antinfiammatoria ed analgesica, riducendo il dolore nell?animale da latte e favorendo il ripristino della normale fisiologia della ghiandola mammaria. The Applicant has surprisingly discovered that the intracanicular administration of ozonated vegetable oil? able to treat or prevent mastitis in a dairy animal. Without wanting to be tied to any theory, the presence of peroxides in the ozonated oil? able to prevent or treat pathogenic infections by destroying bacterial and/or fungal cells. Furthermore, the ozonated vegetable oil has a healing action thanks to the ability to stimulate fibroblasts and induce neoangiogenesis. Finally, the administration of ozonizing oil by endocanicular route has an anti-inflammatory and analgesic action, reducing pain in the dairy animal and favoring the restoration of the normal physiology of the mammary gland.
Un secondo aspetto della presente invenzione riguarda un kit comprende almeno un dispositivo per una somministrazione endocanicolare ed un olio vegetale ozonizzato. Preferibilmente, il dispositivo per la somministrazione endocanicolare ? una siringa. A second aspect of the present invention relates to a kit comprising at least one device for intracanicular administration and an ozonated vegetable oil. Preferably, the intracanicular administration device is a syringe.
In una forma di realizzazione, l?olio vegetale comprende acido oleico (C18:1) e acido linoleico (C18:2) in quantit? complessiva maggiore o uguale a 35% in peso. Preferibilmente, l?olio vegetale comprende complessivamente circa 35-85% in peso, preferibilmente circa 50-80% in peso, pi? preferibilmente circa 55?75% in peso, di acido oleico (C18:1) e acido linoleico (C18:2). In one embodiment, the vegetable oil comprises oleic acid (C18:1) and linoleic acid (C18:2) in amounts greater than or equal to 35% by weight. Preferably, the vegetable oil comprises overall about 35-85% by weight, preferably about 50-80% by weight, plus? preferably about 55-75% by weight, of oleic acid (C18:1) and linoleic acid (C18:2).
In una forma di realizzazione, l?olio vegetale ozonizzato ha una viscosit? e indice di perossido controllati, preferibilmente detto olio ? sotto forma di gel stabile. In one embodiment, the ozonated vegetable oil has a viscosity of and peroxide index controlled, preferably said oil ? in the form of a stable gel.
Preferibilmente, l?olio vegetale ozonizzato ha un indice di perossido IP ? 2000 mEq O2/Kg, pi? preferibilmente compreso tra 350 ? 2000 mEq O2/Kg. In una forma di attuazione preferita dell?invenzione, l?olio vegetale ozonizzato ha un indice di perossido compreso tra 350 ? 1000 mEq O2/Kg, preferibilmente tra 400 ? 800 mEq O2/Kg. Preferably, the ozonated vegetable oil has a peroxide index IP ? 2000 mEq O2/Kg, plus? preferably between 350 ? 2000 mEq O2/Kg. In a preferred embodiment of the invention, the ozonated vegetable oil has a peroxide index of between 350 ? 1000 mEq O2/Kg, preferably between 400 ? 800 mEq O2/Kg.
In una forma di realizzazione, l?olio vegetale ozonizzato ? ottenuto con un processo noto al tecnico del settore. In one embodiment, the ozonated vegetable oil is obtained with a process known to those skilled in the art.
In una forma di attuazione dell?invenzione, l?olio vegetale ozonizzato ? scelto nel gruppo costituito da olio di arachidi, olio di mais, olio di girasole, olio di colza, olio di sesamo, olio di riso, olio di germe di grano, olio di semi di canapa, olio di soia, olio di lino, olio di mandorla, olio di neem, olio di nocciola, olio di vinaccioli, olio di semi di zucca e loro miscele. In one embodiment of the invention, the ozonated vegetable oil is selected from the group consisting of peanut oil, corn oil, sunflower oil, rapeseed oil, sesame oil, rice oil, wheat germ oil, hemp seed oil, soybean oil, linseed oil, oil, neem oil, hazelnut oil, grapeseed oil, pumpkin seed oil, and blends thereof.
Preferibilmente, l?olio vegetale ozonizzato non ? olio di oliva, ovvero diverso da un olio derivante dalla spremitura dei frutti dell?ulivo e/o dalla sansa delle olive. Preferably, ozonated vegetable oil is not olive oil, that is different from an oil deriving from the pressing of the fruits of the olive tree and/or from the pomace of the olives.
In una forma di realizzazione alternativa dell?invenzione, l?olio vegetale ozonizzato ? olio di oliva, ovvero un olio derivante dalla spremitura dei frutti dell?ulivo e/o dalla sansa delle olive. In an alternative embodiment of the invention, the ozonated vegetable oil is olive oil, or an oil deriving from the pressing of the fruits of the olive tree and/or from the pomace of the olives.
Un terzo aspetto della presente invenzione si riferisce ad un metodo per il trattamento o la prevenzione di una mastite in un animale da latte. Detto metodo comprende almeno una fase di somministrazione di un olio vegetale ozonizzato o una composizione che lo comprende, come sopra dettagliatamente descritti. A third aspect of the present invention relates to a method for treating or preventing mastitis in a dairy animal. Said method comprises at least one step of administering an ozonated vegetable oil or a composition comprising it, as described in detail above.
In una forma di realizzazione, l?olio ozonizzato ? somministrato a livello mammario, preferibilmente per via endocanicolare, ovvero nel canalicolo mammario. In one embodiment, the ozonated oil is administered at the mammary level, preferably by the endocanicular route, i.e. in the mammary canaliculus.
In una forma di attuazione, l?animale da latte ? un bovino, preferibilmente ? una vacca da latte, oppure ? un ovino, preferibilmente una pecora o una capra. In una forma di realizzazione preferita dell?invenzione, l?animale da latte ? una vacca. In one embodiment, the dairy animal is a bovine, preferably ? a dairy cow, or ? a sheep, preferably a sheep or a goat. In a preferred embodiment of the invention, the dairy animal is a cow.
Preferibilmente, la mastite ? una mastite clinica, ovvero caratterizzata da modificazioni evidenti della ghiandola mammaria e del latte. La mastite clinica ? preferibilmente caratterizzata da un aumento della conta di cellule somatiche nel latte rispetto alla conta di cellule somatiche in condizioni normali, ovvero non patologiche. Preferably, mastitis ? a clinical mastitis, that is characterized by evident modifications of the mammary gland and of the milk. Clinical mastitis? preferably characterized by an increase in the somatic cell count in milk relative to the somatic cell count under normal, i.e., non-pathological conditions.
Preferibilmente, la conta di cellule somatiche nel latte ? superiore a 2,5*10<5 >cellule/ml di latte, preferibilmente superiore a 3*10<5 >cellule/ml di latte. Preferably, the somatic cell count in milk ? higher than 2.5*10<5 >cells/ml of milk, preferably higher than 3*10<5 >cells/ml of milk.
Preferibilmente, la mastite ? una mastite subclinica, ovvero non sono evidenti modificazioni a livello della ghiandola mammaria e del latte. La mastite subclinica ? preferibilmente caratterizzata da una riduzione della quantit? del latte prodotto e ad un aumento della conta di cellule somatiche nel latte rispetto alla conta di cellule somatiche in condizioni Preferably, mastitis ? a subclinical mastitis, ie there are no obvious changes in the mammary gland and milk. Subclinical mastitis? preferably characterized by a reduction in the quantity? of milk produced and an increase in somatic cell counts in milk relative to somatic cell counts under conditions
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102021000020846A IT202100020846A1 (en) | 2021-08-03 | 2021-08-03 | NEW VETERINARY USE OF A VEGETABLE OIL |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102021000020846A IT202100020846A1 (en) | 2021-08-03 | 2021-08-03 | NEW VETERINARY USE OF A VEGETABLE OIL |
Publications (1)
Publication Number | Publication Date |
---|---|
IT202100020846A1 true IT202100020846A1 (en) | 2023-02-03 |
Family
ID=78212531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IT102021000020846A IT202100020846A1 (en) | 2021-08-03 | 2021-08-03 | NEW VETERINARY USE OF A VEGETABLE OIL |
Country Status (1)
Country | Link |
---|---|
IT (1) | IT202100020846A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100366684B1 (en) * | 2000-05-01 | 2003-01-09 | 주식회사 오존피아 | Oil-based topical preparation including ozone and method of preparation thereof |
JP2005162995A (en) * | 2003-12-05 | 2005-06-23 | Koichi Arai | Device for producing ozonized oil and device for producing ozonide |
EP3620158A1 (en) * | 2013-05-01 | 2020-03-11 | National University of Ireland Galway | Antimicrobial compositions and methods for their production |
US20210007360A1 (en) * | 2018-03-29 | 2021-01-14 | Ahmet Ümit SABANCI | Solutions comprising ozonized oil |
-
2021
- 2021-08-03 IT IT102021000020846A patent/IT202100020846A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100366684B1 (en) * | 2000-05-01 | 2003-01-09 | 주식회사 오존피아 | Oil-based topical preparation including ozone and method of preparation thereof |
JP2005162995A (en) * | 2003-12-05 | 2005-06-23 | Koichi Arai | Device for producing ozonized oil and device for producing ozonide |
EP3620158A1 (en) * | 2013-05-01 | 2020-03-11 | National University of Ireland Galway | Antimicrobial compositions and methods for their production |
US20210007360A1 (en) * | 2018-03-29 | 2021-01-14 | Ahmet Ümit SABANCI | Solutions comprising ozonized oil |
Non-Patent Citations (1)
Title |
---|
SCIORSCI R L ET AL: "Ozone therapy in veterinary medicine: A review", RESEARCH IN VETERINARY SCIENCE, BRITISH VETERINARY ASSOCIATION, LONDON, GB, vol. 130, 25 March 2020 (2020-03-25), pages 240 - 246, XP086117973, ISSN: 0034-5288, [retrieved on 20200325], DOI: 10.1016/J.RVSC.2020.03.026 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104114166A (en) | Antimicrobial compositions comprising dgla, 15-OHEPA and/or 15-HETRE and methods of use thereof | |
KR20110011334A (en) | Composition of comprising bee-venoms for treating acne | |
US9931366B2 (en) | Topical pharmaceutical bases for wound and scar treatment | |
WO2010134827A1 (en) | Extended acting oxygen generating composition for treating microbial infections | |
IT202100020846A1 (en) | NEW VETERINARY USE OF A VEGETABLE OIL | |
CN111956664A (en) | Composition for pets and application thereof | |
EP3038631A1 (en) | Anti-inflammatory compositions, methods and uses thereof | |
CN106267329A (en) | A kind of plants essential oil gel dressing and its preparation method and application | |
El Sakka et al. | Comparison between topical application of honey, bees wax and olive oil propolis extract and nystatin for treatment of diaper dermatitis in infants | |
KR20110092509A (en) | Composition for treating bovine mastitis | |
CN103705912A (en) | Composite lysozyme oral spray and preparation method thereof | |
WO2016120478A1 (en) | Pharmaceutical compositions and plant protection agents containing oxygen-enriched vegetable oils or fatty acids | |
US7476379B1 (en) | Emu-based formulations for the treatment of damaged skin by inhibiting microbial and fungal activity | |
US20170368123A1 (en) | Coniferous resin for treating and preventing sterile inflammation | |
US20040214891A1 (en) | Method for inhibiting pathogenic bacteria and fungi growth and microbicidal composition | |
González-Corrales et al. | Formulation and antimicrobial activity evaluation of a 0.2% chlorhexidine canine mouthwash with essential oils | |
US20240065998A1 (en) | Monoacylglycerol and free fatty acid-based compositions, methods of manufacturing and use of the same | |
CN105265995B (en) | Application of perilla oil as potassium sorbate antibacterial synergist | |
Nividita Puri | Holistic approach of oil pulling in the dental world A literature review | |
US11833230B1 (en) | Root canal irrigant from Rosa damascena mill | |
FI129488B (en) | Salve composition, method of manufacture and use of the composition | |
Aqib | Alternative therapeutic approach to treat canine demodicosis | |
JP2013142085A (en) | New method and new composition for sterilization/antifungal treatment to skin, vagina and oral cavity, formed by dissolving sterilizing/antifungal component into water-soluble viscous component | |
AU2006203630B2 (en) | Intramammary formulations | |
KR20240000210A (en) | Ointment Composition for Treating Bovine Dermatophytosis(Psoriasis) |